Display options
Cite
Lefranc F, Mathieu V, Kiss R. Galectin-1-mediated biochemical controls of melanoma and glioma aggressive behavior. World J Biol Chem. 2011;2(9):193-201doi: 10.4331/wjbc.v2.i9.193.
Lefranc, F., Mathieu, V., & Kiss, R. (2011). Galectin-1-mediated biochemical controls of melanoma and glioma aggressive behavior. World journal of biological chemistry, 2(9), 193-201. https://doi.org/10.4331/wjbc.v2.i9.193
Lefranc, Florence, et al. "Galectin-1-mediated biochemical controls of melanoma and glioma aggressive behavior." World journal of biological chemistry vol. 2,9 (2011): 193-201. doi: https://doi.org/10.4331/wjbc.v2.i9.193
Lefranc F, Mathieu V, Kiss R. Galectin-1-mediated biochemical controls of melanoma and glioma aggressive behavior. World J Biol Chem. 2011 Sep 26;2(9):193-201. doi: 10.4331/wjbc.v2.i9.193. PMID: 21949569; PMCID: PMC3178756.
Copy Download .nbib Format: NLM
Share it on

World J Biol Chem. 2011 Sep 26;2(9):193-201. doi: 10.4331/wjbc.v2.i9.193.

Galectin-1-mediated biochemical controls of melanoma and glioma aggressive behavior.

World journal of biological chemistry

Florence Lefranc, Véronique Mathieu, Robert Kiss

Affiliations

  1. Florence Lefranc, Véronique Mathieu, Robert Kiss, Laboratory of Toxicology, Faculty of Pharmacy, Université Libre de Bruxelles, Brussels 1050, Belgium.

PMID: 21949569 PMCID: PMC3178756 DOI: 10.4331/wjbc.v2.i9.193

Abstract

Gliomas and melanomas are associated with dismal prognosis because of their marked intrinsic resistance to proapoptotic stimuli, such as conventional chemotherapy and radiotherapy, as well as their ability to escape immune cell attacks. In addition, gliomas and melanomas display pronounced neoangiogenesis. Galectin-1 is a hypoxia-sensitive protein, which is abundantly secreted by glioma and melanoma cells, which displays marked proangiogenic effects. It also provides immune tolerogenic environments to melanoma and glioma cells through the killing of activated T cells that attack these tumor cells. Galectin-1 protects glioma and melanoma cells against cytotoxic insults (including chemotherapy and radiotherapy) through a direct role in the unfolded protein response. Altogether, these facts clearly point to galectin-1 as an important target to be combated in gliomas and melanomas in order to: (1) weaken the defenses of these two types of cancers against radiotherapy, chemotherapy and immunotherapy/vaccine therapy; and (2) reinforce antiangiogenic therapies. In the present article, we review the biochemical and molecular biology-related pathways controlled by galectin-1, which are actually beneficial for melanoma and glioma cells, and therefore detrimental for melanoma and glioma patients.

Keywords: Biochemical pathways; Galectin-1; Glioma; Melanoma

References

  1. J Neuropathol Exp Neurol. 2008 May;67(5):456-69 - PubMed
  2. Neuropathol Appl Neurobiol. 1999 Aug;25(4):319-30 - PubMed
  3. J Neurosci Res. 2000 Mar 15;59(6):722-30 - PubMed
  4. Cancer Res. 2010 Aug 1;70(15):6216-24 - PubMed
  5. FEBS Lett. 2008 Apr 16;582(9):1362-8 - PubMed
  6. J Biol Chem. 2002 Oct 4;277(40):37169-75 - PubMed
  7. Autoimmun Rev. 2009 Mar;8(5):360-3 - PubMed
  8. Glycobiology. 2010 Oct;20(10):1199-207 - PubMed
  9. Toxicol Appl Pharmacol. 2008 Jun 1;229(2):172-83 - PubMed
  10. Glia. 2001 Mar 1;33(3):241-55 - PubMed
  11. Biochim Biophys Acta. 2002 Sep 19;1572(2-3):285-93 - PubMed
  12. Oncologist. 2011;16(1):5-24 - PubMed
  13. Curr Opin Oncol. 2006 Mar;18(2):189-96 - PubMed
  14. Cancer Cell. 2004 Mar;5(3):241-51 - PubMed
  15. Cancer Res. 2004 May 1;64(9):3112-8 - PubMed
  16. J Neurosurg. 2008 Aug;109(2):273-84 - PubMed
  17. Immunol Rev. 2009 Jul;230(1):144-59 - PubMed
  18. Brain Pathol. 2001 Jan;11(1):12-26 - PubMed
  19. Proc Natl Acad Sci U S A. 2006 Oct 24;103(43):15975-80 - PubMed
  20. Curr Pharm Biotechnol. 2012 Sep;13(11):2299-307 - PubMed
  21. Biochem Biophys Res Commun. 1995 Apr 17;209(2):760-7 - PubMed
  22. J Invest Dermatol. 2007 Oct;127(10):2399-410 - PubMed
  23. Expert Rev Anticancer Ther. 2006 May;6(5):719-32 - PubMed
  24. Carcinogenesis. 2010 Aug;31(8):1367-75 - PubMed
  25. J Biol Chem. 1994 Aug 19;269(33):20807-10 - PubMed
  26. Oncogene. 2003 May 19;22(20):3138-51 - PubMed
  27. Methods Enzymol. 2010;480:199-244 - PubMed
  28. J Clin Oncol. 2005 Dec 10;23(35):8932-41 - PubMed
  29. Scand J Immunol. 2007 Aug-Sep;66(2-3):143-58 - PubMed
  30. Glycobiology. 2006 Nov;16(11):137R-157R - PubMed
  31. Lab Invest. 2002 Feb;82(2):147-58 - PubMed
  32. J Immunol. 2006 Jul 1;177(1):216-26 - PubMed
  33. Neoplasia. 2009 May;11(5):485-96 - PubMed
  34. Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5256-61 - PubMed
  35. Lancet Oncol. 2009 May;10(5):459-66 - PubMed
  36. Melanoma Res. 2011 Jun;21(3):165-74 - PubMed
  37. Nat Immunol. 2009 Sep;10(9):981-91 - PubMed
  38. Melanoma Res. 2010 Apr;20(2):77-84 - PubMed
  39. Cancer Genomics Proteomics. 2008 Nov-Dec;5(6):293-300 - PubMed
  40. Eur J Pharmacol. 2009 Dec 25;625(1-3):234-46 - PubMed
  41. Biochem Biophys Res Commun. 2005 Sep 16;335(1):27-35 - PubMed
  42. Methods Enzymol. 2006;417:247-56 - PubMed
  43. Br J Cancer. 2005 Apr 11;92(7):1188-92 - PubMed
  44. J Neuropathol Exp Neurol. 2002 Jul;61(7):585-96 - PubMed
  45. Expert Rev Neurother. 2011 Apr;11(4):533-43 - PubMed
  46. N Engl J Med. 2006 Jul 6;355(1):51-65 - PubMed
  47. J Proteomics. 2009 Aug 20;72(6):1019-30 - PubMed
  48. Arch Biochem Biophys. 2008 Oct 1;478(1):18-25 - PubMed
  49. Hematol Oncol Clin North Am. 2009 Jun;23(3):431-46, vii-viii - PubMed
  50. J Clin Oncol. 2005 Apr 1;23(10):2411-22 - PubMed
  51. Nat Rev Cancer. 2011 Jun;11(6):393-410 - PubMed
  52. Nucleic Acids Res. 2006;34(18):5166-74 - PubMed
  53. Brain Pathol. 2010 Jan;20(1):17-27 - PubMed
  54. Curr Cancer Drug Targets. 2009 May;9(3):391-7 - PubMed
  55. Int J Cancer. 2011 Jul 1;129(1):1-8 - PubMed
  56. Nature. 1995 Dec 14;378(6558):736-9 - PubMed
  57. J Proteome Res. 2007 Feb;6(2):869-75 - PubMed
  58. Brain Pathol. 2009 Oct;19(4):694-712 - PubMed
  59. Int J Cancer. 2001 Jan 15;91(2):167-72 - PubMed
  60. Glycoconj J. 2004;19(7-9):507-15 - PubMed
  61. Glycoconj J. 2004;19(7-9):467-77 - PubMed
  62. Oncologist. 2007 Dec;12(12):1395-403 - PubMed
  63. Pigment Cell Melanoma Res. 2009 Apr;22(2):166-74 - PubMed
  64. Nat Rev Cancer. 2005 Jan;5(1):29-41 - PubMed
  65. Cell Mol Life Sci. 2003 Feb;60(2):267-76 - PubMed
  66. Future Oncol. 2009 May;5(4):543-57 - PubMed
  67. J Neurooncol. 2009 May;92(3):317-35 - PubMed
  68. Mol Biol Evol. 2004 Jul;21(7):1177-87 - PubMed
  69. Mol Oncol. 2011 Apr;5(2):137-49 - PubMed
  70. N Engl J Med. 2005 Mar 10;352(10):987-96 - PubMed
  71. Brain Pathol. 2010 Jan;20(1):39-49 - PubMed
  72. Oncol Rep. 2007 Aug;18(2):483-8 - PubMed
  73. J Cell Biol. 2005 Oct 24;171(2):373-81 - PubMed

Publication Types